Ben Ho Park, MD, PhD | Authors

TORn in Two Over Breast Cancer Drug Resistance

January 15, 2013

Knowing the genetic makeup of patient tumors permits the development of new DNA-based diagnostics, such as BEAMing and PARE. By incorporating these new tools into future trials, we should be able to concurrently learn about drug resistance and significantly improve patient responses.